Pronzato P, Amoroso D, Bertelli G, Conte P F, Cusimano M P, Ciottoli G B, Gulisano M, Lionetto R, Rosso R
Istituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica, Genova, Italy.
Br J Cancer. 1989 Feb;59(2):251-3. doi: 10.1038/bjc.1989.51.
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
30例先前接受过治疗的转移性乳腺癌患者进入了一项口服氯尼达明的II期研究。28例患者可评估毒性，25例可评估疗效。4例患者（16%）获得部分缓解，11例患者（44%）病情稳定，10例患者（40%）病情进展。毒性反应可接受，主要包括肌痛（39%的患者）和乏力（21.4%）。未观察到骨髓毒性。该药物在先前接受过治疗的转移性乳腺癌中具有活性，由于其独特的作用方式和毒性，值得与细胞毒性化疗联合进行评估。
